Who Paid My Doc
Walter Devine
Anatomic Pathology San Francisco, CA Medical Doctor
NPI 1376998476 CMS profile 1427677
505 Parnassus Ave, Ucsf Department Of Pathology, San Francisco, CA 94143
General payments
$8,561
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Walter Devine of San Francisco, CA is reported in the CMS Open Payments database as having received $8,561 across 10 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 87th percentile of Anatomic Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $55 | 2 | |
| 2024 | General | $113 | 1 | |
| 2023 | General | $8,393 | 7 |
Beside peers
- Walter Devine
- Anatomic Pathology median
- Middle half of Anatomic Pathology
- National median
In program year 2025, general payments to Walter Devine were reported at $55. Among 419 Anatomic Pathology profiles paid that year, the median was $110 and the middle half received between $28 and $974.
Show as a table
| Year | Walter Devine | Anatomic Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $112 | $31–$404 | $163 |
| 2020 | $0 | $185 | $25–$4,265 | $114 |
| 2021 | $0 | $121 | $24–$2,629 | $132 |
| 2022 | $0 | $121 | $31–$1,816 | $149 |
| 2023 | $8,393 | $96 | $28–$1,008 | $160 |
| 2024 | $113 | $103 | $28–$1,069 | $164 |
| 2025 | $55 | $110 | $28–$974 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 3 billing codesPaid by Medicare
$27,564
Medicare patients
611
Services billed
674
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Cancer | 72% | |
| High blood pressure | 64% | |
| Arthritis | 35% | |
| Diabetes | 24% | |
| Ischemic heart disease | 20% | |
| Chronic kidney disease | 20% | |
| Osteoporosis | 19% | |
| Atrial fibrillation | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
10 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Anatomic Pathology in California
Peter Tontonoz
Anatomic Pathology · Los Angeles, CA
Kenneth Widder
Anatomic Pathology · Rancho Santa Fe, CA
Sheeja Pullarkat
Anatomic Pathology · Los Angeles, CA
Lawrence Weiss
Anatomic Pathology · Aliso Viejo, CA
Alfred Lui
Anatomic Pathology · Torrance, CA
Meredith Miller
Anatomic Pathology · Redwood City, CA
Related records
Anatomic Pathology in California
Practitioners in the same specialty and state, ranked by reported value.
All Anatomic Pathology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.